Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors while in the central nervous method, conolidine modulates alternate molecular targets. A Science Advancements analyze found that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://williamh531cdd0.wikisona.com/user